What Graymark Capital does

Graymark Capital is a privately held commercial real estate investment firm founded in 2005 and headquartered in San Francisco, California. The firm acquires and manages institutional-quality R&D, industrial, advanced manufacturing, bioscience, and creative office properties in supply-constrained Western U.S. markets. Since 2012, Graymark has purchased 37 properties comprising over 4.3 million square feet and more than $2.0 billion in value, with cumulative transactions exceeding $3 billion when including pre-2012 activity.

The firm's core strategy is value-add investment: acquiring underperforming assets at discounts to replacement cost (typically 55-65% of replacement cost), then executing physical rehabilitations, professional management, leasing, and repositioning to capture upside through below-market rent rollovers and disposition. Graymark operates two principal investment programs: the Gray Matter Life Science Program focused on office-to-lab conversions in major life science clusters, and the Medium Term Net Lease (MTNL) Program targeting single-tenant R&D and industrial assets under 3-7 year leases. The firm targets "modern workplace" tenants in life sciences, technology, advanced manufacturing, and creative office sectors.

Graymark generates revenue through management fees, rental income, refinancing proceeds, and disposition gains on its investment portfolio. The firm invests alongside institutional capital partners in every acquisition, with recurring joint venture relationships including BentallGreenOak, Nuveen Real Estate, Jadian Capital, Blue Vista Capital Management, New York Life Real Estate Investors, Argosy Real Estate Partners, and others. Tenants range from Fortune 500 companies (e.g., Qualcomm, Dexcom, Infineon, Wyndham, Progressive, Waste Management, Mylan Pharmaceuticals) to early-stage growth companies in life sciences and technology. The firm is led by three principals—Brian Hecktman (CEO), Jeff Hoppen (COO/CFO), and Rick Lafranchi (CIO)—supported by a lean team of senior investment, asset management, and finance professionals.

Name

Graymark Capital

Legal name

Graymark Capital, Inc.

Website

https://graymarkcapital.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Graymark Capital is a privately held San Francisco-based commercial real estate investment firm that acquires, repositions, and manages institutional-quality R&D, life science, industrial, and creative office properties across the Western U.S., executing value-add strategies alongside institutional joint venture partners and serving tenants from Fortune 500 companies to growth-stage firms.

Ownership category

akta.pro rank

Product category

Commercial Real Estate Investment

NAICS

Other Investment Pools and Funds (5259)

SIC

Real Estate Dealers (For Their Own Account) (6532)

akta.pro primary industry

Real Estate Funds — Value-Add (FSANAEAH)

akta.pro secondary industry

Real Estate Funds — Core-Plus (FSANAEAG)

Keywords

• Commercial real estate investing
• Value-add acquisitions
• Life science conversions
• Institutional real estate
• Joint venture partnerships

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Real Estate Investment Returns: Graymark Capital generates returns through acquisition of underperforming or undervalued commercial properties, executing value-add strategies including renovation, repositioning, and lease-up, then selling properties at a profit or refinancing. The company invests alongside institutional investors in every acquisition, aligning interests with stakeholders. Revenue is realized through property sales, refinancing proceeds, and ongoing rental income from tenant leases.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Graymark Capital is a commercial real estate investment firm that acquires and manages institutional-quality R&D, industrial, advanced manufacturing, bioscience, and creative office properties across major Western U.S. markets. The firm executes value-add strategies including physical rehabilitation, professional management, leasing, and repositioning of underperforming or undervalued assets, typically acquired at 55–65% of replacement cost. Capital is deployed alongside institutional co-investment partners on every acquisition, with returns realized through property sales, refinancing, and stabilized rental income.

Product overview

Graymark Capital is a commercial real estate investment firm that operates as a single unified investment platform rather than a multi-module software product. The company manages two primary investment initiatives: the Gray Matter life science program focused on office-to-lab conversions, and the Medium Term Net Lease (MTNL) Program targeting single-tenant R&D and industrial properties. The firm's investment strategy encompasses acquiring, managing, and repositioning institutional-quality R&D, industrial, advanced manufacturing, bioscience, and creative office properties across the Western United States. Graymark's portfolio includes a diverse range of commercial properties spanning multiple markets including the San Francisco Bay Area, San Diego, Los Angeles, Austin, Seattle, Portland, and Hawaii.

Differentiator

Problem solved

Functional benefit

Brands

• Gray Matter: Life science initiative by Graymark Capital focusing on life science conversion projects in the Western United States, including office-to-lab conversions in San Francisco Bay Area, San Diego, Los Angeles, and Austin.

Products and services

• Gray Matter Life Science Program Life science investment initiative focused on acquiring and converting office/R&D properties to life science use in major Western U.S. markets including the San Francisco Bay Area, San Diego, Los Angeles, and Austin. The program targets life science conversion projects and serves institutional investors seeking exposure to supply-constrained life science real estate.
• Medium Term Net Lease (MTNL) Program Investment program focused on well-located infill office/R&D/industrial assets leased to creditworthy tenants under 3 to 7-year lease terms in major Western U.S. markets. Designed for institutional investors seeking stable net lease exposure to supply-constrained infill markets.
• Value-Add Commercial Real Estate Investment and Asset Management Core service offering that acquires institutional-quality R&D, industrial, advanced manufacturing, bioscience, and creative office properties in Western U.S. infill markets at discounts to replacement cost, then executes value-add strategies including physical rehabilitation, professional management, leasing, and repositioning. Delivered to institutional co-investment partners with capital deployed alongside Graymark principals on every acquisition.

Quantifiable outcome

• Since 2012, purchased 37 properties comprising over 4.3 million square feet and over $2.0 billion of value
• +2 more outcomes

Named customers20 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Legacy Partners: California-based CRE firm focused on multifamily, office, and life science development/investment. Comparable in size, regional focus on Western U.S. infill markets, and exposure to life science and modern office repositioning.
• Blue Vista Capital Management: Recurring JV partner since 2015 across Carlsbad, San Diego, Pasadena, and Redmond assets. Chicago-based real estate private equity firm with $5.7B+ in total capitalization, focused on value-add and opportunistic strategies similar to Graymark's.
• Rialto Capital Management: JV partner on 650 Clyde Court in Mountain View. Diversified real estate investment, management, development and finance company (Lennar subsidiary) — comparable in middle-market value-add CRE execution.
• Jadian Capital: JV partner on life science acquisitions including Fremont Labs and 2051 Palomar Airport Road. A New York/Stamford-based investment firm focused on real estate and asset-intensive businesses, with direct overlap in life science conversion strategy.
• Argosy Real Estate Partners: JV partner on the 120 Via Merida life science conversion. Specializes in opportunistic, value-add, core-plus, and Opportunity Zone CRE investments in the middle market — directly comparable in size, strategy, and target geography.
• Eightfold Real Estate Capital: JV partner on San Francisco Jackson Square and Pasadena creative office/R&D acquisitions. Operates discretionary closed-end funds targeting value-add U.S. real estate — directly comparable investment strategy and asset class.

Broad incumbents

• Stockbridge Capital Group: San Francisco-based CRE investment manager with value-add and core-plus strategies across U.S. markets including the West Coast. Operates at larger scale than Graymark with overlapping infill market focus and institutional LP relationships.
• BentallGreenOak: JV partner on the Austin Met Center portfolio and San Carlos life science recapitalization. Global CRE investment manager with ~$70B AUM serving 750+ institutional clients — a much larger incumbent with overlapping value-add and life science capabilities.
• Rockefeller Group: National CRE investment and development firm with comparable value-add strategies in major U.S. markets. Larger incumbent with similar institutional capital structure and asset repositioning capabilities.
• Nuveen Real Estate: JV partner on 150 Industrial Road (San Carlos) and 101 PCH (El Segundo) acquisitions. One of the world's largest investment managers with ~$130B AUM, with broad U.S. value-add and life science coverage that overlaps with Graymark's focus markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Graymark Capital